A61K 2039/5256
Expressing foreign proteins
Official title: {expressing foreign proteins}
A61K2039/5256 (Expressing foreign proteins) appears on 1,724 US grants and 2,782 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,724
- Published applications
- 2,782
- Assignees
- 1,024
- Inventors
- 4,062
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 10 | 0 |
| 1998 | 31 | 0 |
| 1999 | 17 | 0 |
| 2000 | 24 | 0 |
| 2001 | 31 | 7 |
| 2002 | 19 | 45 |
| 2003 | 32 | 91 |
| 2004 | 29 | 110 |
| 2005 | 27 | 113 |
| 2006 | 45 | 101 |
| 2007 | 49 | 98 |
| 2008 | 47 | 92 |
| 2009 | 64 | 115 |
| 2010 | 80 | 157 |
| 2011 | 77 | 138 |
| 2012 | 69 | 115 |
| 2013 | 53 | 102 |
| 2014 | 74 | 96 |
| 2015 | 75 | 109 |
| 2016 | 81 | 87 |
| 2017 | 105 | 133 |
| 2018 | 77 | 120 |
| 2019 | 96 | 109 |
| 2020 | 88 | 134 |
| 2021 | 86 | 131 |
| 2022 | 79 | 130 |
| 2023 | 73 | 154 |
| 2024 | 59 | 140 |
| 2025 | 65 | 104 |
| 2026 | 51 | 51 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- AAV5-based vaccine against SARS-CoV-215 Sep 2026US 12,734,235 B2
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Kits for trichinella vaccination based on a prime-boost sequential immunization regimen1 Oct 2026US 2026/0295024 A1Jilin University
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Vaccine with reduced anti-vector antigenicity24 Sep 2026US 2026/0284178 A1
- A viral vector and a vaccine composition comprising the vector24 Sep 2026US 2026/0284181 A1Rokote Laboratories Finland Oy
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014